CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice

Perry Tsai, University of North Carolina at Chapel Hill
William O Thayer, University of North Carolina at Chapel Hill
Liqin Liu, MacroGenics, Inc.
Guido Silvestri, Emory University
Jeffrey L Nordstrom, MacroGenics, Inc.
J Victor Garcia, University of North Carolina at Chapel Hill

Journal Title: Molecular Therapy — Oncolytics
Volume: Volume 3
Publisher: Nature Publishing Group | 2016-03-02, Pages 15024-15024
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1038/mto.2015.24
Permanent URL: https://pid.emory.edu/ark:/25593/rmg40

Final published version: http://dx.doi.org/10.1038/mto.2015.24

Copyright information:
© 2016, Rights Managed by Nature Publishing Group
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed September 14, 2020 11:35 AM EDT
CD19xCD3 DART protein mediates human B-cell depletion \textit{in vivo} in humanized BLT mice

Perry Tsai\textsuperscript{1}, William O Thayer\textsuperscript{1}, Liqin Liu\textsuperscript{2}, Guido Silvestri\textsuperscript{3}, Jeffrey L Nordstrom\textsuperscript{2} and J Victor Garcia\textsuperscript{1}

Novel therapeutic strategies are needed for the treatment of hematologic malignancies; and bispecific antibody-derived molecules, such as dual-affinity re-targeting (DART) proteins, are being developed to redirect T cells to kill target cells expressing tumor or viral antigens. Here we present our findings of specific and systemic human B-cell depletion by a CD19xCD3 DART protein in humanized BLT mice. Administration of the CD19xCD3 DART protein resulted in a dramatic sustained depletion of human CD19\textsuperscript{+} B cells from the peripheral blood, as well as a dramatic systemic reduction of human CD19\textsuperscript{+} B-cell levels in all tissues (bone marrow, spleen, liver, lung) analyzed. When human CD8\textsuperscript{+} T cells were depleted from the mice, no significant B-cell depletion was observed in response to CD19xCD3 DART protein treatment, confirming that human CD8\textsuperscript{+} T cells are the primary effector cells in this \textit{in vivo} model. These studies validate the use of BLT humanized mice for the \textit{in vivo} evaluation and preclinical development of bispecific molecules that redirect human T cells to selectively deplete target cells.

\textit{Molecular Therapy — Oncolytics} (2016) 3, 15024; doi:10.1038/mto.2015.24; published online 2 March 2016

\textbf{INTRODUCTION}

Therapies using targeted monoclonal antibodies have proven safe and effective against hematologic malignancies.\textsuperscript{1} In particular, rituximab, which targets the B-cell marker CD20, has greatly enhanced outcomes in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia. However, not all patients respond to rituximab, and many of those who do eventually experience disease relapse.\textsuperscript{2–5} Monoclonal antibody therapies directed against other B-cell antigens, such as CD19, CD22, CD30, CD37, CD40, or CD52, are in development at different stages of preclinical/clinical testing.\textsuperscript{5–11} B-cell–targeted therapies with novel mechanisms of action are still necessary in order to improve cure rates, and innovative therapies could prove cost-effective in the treatment of hematologic malignancies.\textsuperscript{12}

Existing monoclonal antibody therapies rely on the action of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity,\textsuperscript{13,14} or utilize a conjugated toxin or radio-labeled isotope.\textsuperscript{15} Other strategies harness the ability of cytotoxic T lymphocytes (CTLs) to kill target cells, relying on \textit{ex vivo} manipulation to expand tumor-specific CTLs\textsuperscript{16} or to express chimeric antigen receptors\textsuperscript{17}; but these approaches are limited by major histocompatibility (MHC) restriction in tumor-specific CTLs, as well as scalability and risks involved.\textsuperscript{18}

Recently, the development of bispecific T-cell-redirecting antibody-derived molecules has made possible treatment strategies that bypass the requirement for MHC matching or \textit{ex vivo} manipulation and expansion of CTLs. These bispecific molecules bind simultaneously to a receptor on T cells and to a specific antigen on a target cell, thus redirecting T cells to kill the target cells. One example is blinatumomab, a bispecific T cell engager (BiTE) molecule targeting CD19, which demonstrated complete responses in 72% of patients with persistent or relapsed minimal residual disease and a median overall survival of 9 months.\textsuperscript{18}

To build upon this success, newer generations of bispecific molecules have been developed, like the dual-affinity re-targeting (DART) molecules. DART molecules differ from BiTE molecules in two ways: there is no intervening linker sequence between the V regions of DART molecules, and there are two cysteine residues at the C-terminus of each chain which form a disulfide bridge.\textsuperscript{19,20} In a previous report comparing DART molecules with BiTE molecules, DART molecules seemed to perform better than BiTE molecules with respect to antigen binding, ability to crosslink target/effector cells, induction of T-cell activation markers, EC\textsubscript{50} for target cell lysis, and maximal target cell lysis.\textsuperscript{20,21} A CD123xCD3 DART protein (directed against human CD3 and human CD123) was active against human AML cell line engraftments in NOD/SCID mice reconstituted with human peripheral blood mononuclear cells (PBMCs), and, due to its crossreactivity to both antigens from cynomolgus monkeys, depleted CD123\textsuperscript{+} cells when administered to the monkeys.\textsuperscript{22} A CD19xCD3 DART protein (directed against human CD19 and human T-cell receptor αβ subunit) was active against human B-cell lymphoma xenografts in NOD/SCID mice reconstituted with human PBMCs.\textsuperscript{23} A CD19xCD3 DART protein in an extended half-life format was active against B-cell lymphoma xenografts in mice reconstituted with human PBMCs, and,
due to its crossreactivity to both antigens from cynomolgus monkeys, depleted CD19+ B cells in peripheral blood and lymph nodes when administered to the monkeys. However, there has yet to be a systemic in vivo evaluation of the effect of CD19xCD3 DART molecules on human immune cells generated de novo from hematopoietic stem cells.

Bone marrow–liver–thymus (BLT) humanized mice could serve as an excellent preclinical model for the in vivo evaluation of CD19xCD3 DART molecules. BLT mice are generated by implanting human thymus and liver tissue into sublethally irradiated NOD/SCID-γ chain null mice, followed by transplanting autologous human CD34+ hematopoietic stem cells. BLT mice develop robust levels of human hematopoietic cells throughout the body, including T cells, B cells, monocytes/macrophages, and dendritic cells; and this model has been utilized in the study of B cells, immune reconstitution, and HIV infection.

In this manuscript, we evaluated the efficacy of human B-cell depletion by a CD19xCD3 DART protein, in which the binding arms are equivalent to those utilized in blinatumomab, in BLT humanized mice. Our results demonstrate that this DART molecule is effective at depleting human B cells in peripheral blood and tissues. We also show that this effect occurred on mature B cells and that progenitor cells remain functionally capable of generating new human B cells in the bone marrow. Finally, we demonstrate that B-cell depletion by this CD19xCD3 DART molecule is dependent on human CD8+ T cells. Together, our results provide in vivo evidence of the functional capacity of T-cell–redirecting DART proteins and validate the utilization of the BLT humanized mouse model for the preclinical evaluation of these molecules.

RESULTS

Depletion of human CD19+ B cells in peripheral blood after administration of CD19xCD3 DART protein

In order to evaluate the efficacy of CD19xCD3 DART proteins to deplete human B cells in vivo, we utilized BLT humanized mice. BLT mice were constructed as previously described. The mice used for all experiments were 16–20 weeks post humanization procedure, and they were well reconstituted with human CD45+ cells (63.5% ± 13.6 SD). Of the human CD45+ cells present in peripheral blood at the beginning of the experiments, 39% ± 9.3 SD expressed human CD19, and 53.3% ± 10.7 SD expressed CD3 on their cell surface. 78.3% ± 6.5 SD of human CD3+ cells expressed human CD4.

For our experiments, we used a CD19xCD3 DART molecule in which the CD19 arm was derived from anti-human CD19 antibody HD37, and the CD3 arm was derived from anti-human CD3 antibody TR66, as described by Moore et al.; these binding arms are equivalent to those of blinatumomab. This bispecific molecule binds to human CD3 on T cells and to human CD19 on B cells, and it recruits the cytotoxic activity of the T cells to kill the target B cells. The CD19xCD3 DART molecule was administered to BLT mice (n = 3) i.v. (1 mg/kg) in two doses, 7 days apart. A similar group of BLT mice was administered vehicle (normal saline, n = 3). Peripheral blood was collected for flow cytometric analysis on days 0, 1, 3, 7, and 11 after the first injection (Figure 1a, gating scheme in Supplementary Figure S1a).

Initially after CD19xCD3 DART molecule administration (day 1), the levels of total human CD45+ cells detected from the peripheral blood dropped to 3.2% ± 1.3 SEM (or 38 ± 11 CD45+ cells per microliter of blood); but this decrease was transient, as the levels of CD45+ cells returned to approximately normal levels by day 3 (Figure 1b,c). With regard to the target human CD19+ B cells, the pretreatment

![Figure 1](https://example.com/figure1.png)

**Figure 1** CD19xCD3 DART protein administration depletes human CD19+ B cells from the peripheral blood. (a) Experimental outline. NSG/BLT mice were administered CD19xCD3 (n = 3, 1 mg/kg i.v.) or vehicle (n = 3) at day 0 and day 7. Peripheral blood (PB) was collected and analyzed at days 0, 1, 3, 7, 11. (b) Percent CD45+ cells out of live cells and (c) number CD45+ cells per microliter detected in PB by flow cytometry (vehicle group in blue; CD19xCD3 group in red). (d) Percent CD19+ cells out of CD45+ cells and (e) number CD19+ cells per microliter detected in PB by flow cytometry (open circle = below limit of quantitation). (Mean ± SEM plotted. P values were calculated by repeated-measures two-way analysis of variance with Sidak’s multiple comparisons test, comparing vehicle versus CD19xCD3. ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.)

![Figure 2](https://example.com/figure2.png)

**Figure 2** CD19xCD3 DART protein administration depletes human CD19+ B cells from the tissues. NSG/BLT mice were administered CD19xCD3 (n = 3, 1 mg/kg intravenously) or vehicle (n = 3) at day 0 and day 7. Tissues were harvested and analyzed at day 11. (a) Percent CD19+ cells out of CD45+ cells and (b) number CD19+ cells detected in tissues by flow cytometry (vehicle group in blue; CD19xCD3 group in red). (Mean ± SEM plotted. P values were calculated by unpaired t-test, comparing vehicle vs. CD19xCD3. ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.)
levels of CD19+ cells in peripheral blood were 27.8% ± 1.5 CD19+ out of CD45+. By day 1 after CD19xCD3 administration, the percentage of CD19+ cells out of CD45+ fell to below limit of quantitation by flow cytometry. The levels of CD19+ cells in the peripheral blood remained lower than 0.1% on days 3, 7, and 11 after CD19xCD3 administration (Figure 1d). This decrease in human CD19+ B cells was also reflected in the absolute numbers of cells. Specifically, the number of CD19+ cells per microliter in the peripheral blood of the CD19xCD3-treated animals was reduced from 413 ± 67 CD19+ cells per microliter to <1 CD19+ cell per microliter of blood (Figure 1e).

In contrast to the extensive decreases in the levels of human CD19+ B cells in the CD19xCD3-treated mice, the animals treated with vehicle maintained relatively high levels of CD19+ cells. It should be noted that the decrease observed in percentage of human CD19+ cells out of CD45+ cells is consistent with the increases in human T-cell reconstitution that occur over time in this animal model (Supplementary Figure S2). However, the number of human CD19+ cells per microliter did not change significantly between day 0 and day 11 in the animals receiving vehicle (Figure 1e). All differences in the levels of human B cells between the CD19xCD3 group and the vehicle group were statistically significant at days 3, 7, and 11.

To evaluate the specificity of the effect of the CD19xCD3 DART molecule, we administered a control DART protein (4420xCD3), with one arm directed against an irrelevant target fluorescein, to BLT mice (n = 4). We did not observe a decrease in the levels of human CD19+ B cells. An increase in the percentage of CD19+ levels was noted 1 day after DART protein administration, but levels returned to normal by day 3 (Supplementary Figure S3).

We also measured the levels of human inflammatory cytokines (IL-1β, IL-6, IL-8, IL-10, IL-12p70, and TNF) in plasma samples from mice treated with vehicle, with control DART molecule, or with CD19xCD3 DART molecule (n = 4 each group). Before treatment, the levels of all cytokines tested were below the limit of quantitation (20 pg/ml) in all mice. One day after treatment, the levels remained below limit of quantitation in the mice treated with vehicle or control DART molecule. In contrast, 1 day after CD19xCD3 treatment, we noted a significant increase in the plasma levels of IL-6, IL-8, and IL-10: 337 ± 122 pg/ml IL-6, 528 ± 110 pg/ml IL-8, 1,800 ± 622 pg/ml IL-10 (mean ± SEM, P < 0.0001 with two-way repeated-measures analysis of variance and Tukey’s multiple comparisons test). By three days after treatment, the cytokine levels in the CD19xCD3-treated mice decreased back to basal levels. Together, these results show (i) a transient increase in cytokine levels in response to CD19xCD3 DART molecule treatment that resolves by 72 hours and (ii) the efficient and specific depletion of human CD19+ B cells from the peripheral blood of BLT humanized mice.

Depletion of human CD19+ B cells in tissues after administration of CD19xCD3 DART protein

In order to determine the systemic effects of the CD19xCD3 DART molecule, we harvested and isolated cells from the bone marrow, spleen, liver, and lung of the animals in the experiment described in Figure 1 at day 11, and measured levels of human CD19+ B cells in each tissue. We observed a marked depletion of CD19+ cells in all the tissues analyzed of the CD19xCD3-treated animals, down to <0.1% (Figure 2a). In contrast, the percentages of CD19+ cells in the tissues from animals that received vehicle remained normal (61.6% ± 0.9 in the bone marrow, 48.3% ± 1.0 in the spleen, 14.2% ± 1.6 in the liver, and 12.1% ± 0.6 in the lung). The absolute numbers of CD19+ cells were reduced over 2,100-fold in the bone marrow of the CD19xCD3-treated animals and over 7,600-fold in the spleen, as compared to vehicle-treated animals. We could not detect CD19+ cells by flow cytometry in the livers and lungs of the mice that received the CD19xCD3 DART molecule (Figure 2b). These differences in CD19+ cell levels were statistically
Human B cell depletion in vivo by DART proteins

P Tsai et al.

Molecular Therapy — Oncolytics (2016) 15024 Official journal of the American Society of Gene & Cell Therapy

Figure 4  CD19xCD3 DART protein administration results in transient differences in the levels of human T cells in the peripheral blood of NSG/BLT mice, and over time there are no significant differences in absolute numbers of human CD8^+ T cells in the peripheral blood or tissues as compared to vehicle-treated mice. NSG/BLT mice were administered CD19xCD3 (n = 3, 1 mg/kg i.v.) or vehicle (n = 3) at day 0 and day 7. Peripheral blood (PB) was collected and analyzed at days 0, 1, 3, 7, 14, 21, and 28; tissues were harvested and analyzed at day 28. (a) Percent CD45^+ cells out of live cells and (b) number CD45^+ cells per microliter detected in peripheral blood by flow cytometry (vehicle group in purple, CD19xCD3 group in brown). (c) Percent CD3^+ cells out of CD45^+ cells and (d) number CD3^+ cells per microliter. (e) Percent CD8^+ cells out of CD3^+ cells and (f) number CD8^+ cells per microliter. (g) Percent CD8^+ cells out of CD3^+ cells and (h) number CD8^+ T cells detected in tissues by flow cytometry. (Mean ± SEM plotted. P values were calculated in a–f by repeated-measures two-way analysis of variance with Sidak’s multiple comparisons test, comparing vehicle versus CD19xCD3. P values were calculated in g and h by unpaired t-test, comparing vehicle versus CD19xCD3. ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Gray diamond indicates data from age-matched NSG/BLT mice, n = 4.)
significant between the vehicle group and the CD19xCD3-treated group across all tissues analyzed. Together, these results demonstrate that the CD19xCD3 DART molecule can effectively deplete human CD19+ B cells from tissues.

Regeneration of human CD19+ B cells after administration of CD19xCD3 DART protein

Next, we sought to investigate the durability of depletion as well as potential for regeneration of human CD19+ B cells after administration of the CD19xCD3 DART molecule. We treated BLT mice with CD19xCD3 or vehicle (n = 3 for each group). We monitored the levels of human CD19+ B cells in peripheral blood at days 1, 3, 7, 14, 21, and 28 after the first injection (Figure 3a).

As in the previous experiment in Figure 1b,c, we observed a depletion of CD19+ cells in the peripheral blood of the CD19xCD3-treated animals over the first 2 weeks. At day 21 after the first injection, the levels of CD19+ cells in the peripheral blood began to increase in the CD19xCD3-treated group. By day 28, the differences in the levels of CD19+ cells were not statistically significant between the vehicle-treated mice and the CD19xCD3-treated mice (Figure 3b,c). Analysis of the levels of CD19+ cells in the tissues at this time point were not significantly different between the animals that received vehicle versus CD19xCD3, indicating that regeneration of the B-cell population had occurred in the DART protein-treated animals (Figure 3d,e).

To confirm that the human CD19+ B cells that were present at day 28 in the CD19xCD3-treated animals were not residual from the pretreatment period, we assessed the developmental stage of the CD19+ cells appearing after CD19xCD3 administration. Specifically, we measured the levels of immature B cells as determined by human CD10 cell surface expression (gating scheme in Supplementary Figure S1b). The percentage of CD10+ cells out of the CD19+ population was significantly higher in the CD19xCD3-treated mice across all tissues analyzed, reaching >90% in the bone marrow, spleen, and liver, and 80% in the lung (Figure 3f). These results demonstrate the production of new B cells in mice previously treated with the CD19xCD3 DART protein.

Effect of CD19xCD3 DART protein administration on the levels of human T cells in vivo

To examine the effect of the CD19xCD3 DART molecule on human T cells in vivo, in particular CD8+ cytotoxic T cells, we measured the levels of human CD45+, CD3+, and CD8+ cells in peripheral blood after two administrations of vehicle or CD19xCD3 (1 mg/kg) 7 days apart, over a period of 4 weeks after the first administration.

Similar to the results presented above (Figure 1), we observed a sharp decline at day 1 of human CD45+ lymphocytes (both percentage and absolute number) in the peripheral blood of CD19xCD3-treated animals (Figure 4a,b). However, this decline was only transient: by day 3, there was no longer a significant difference in the levels of human hematopoietic cells between the vehicle- and the CD19xCD3-treated mice. The levels were again significantly lower in the CD19xCD3-treated group at day 14 (7 days after the second administration), but there was not a significant difference at day 28.

With regard to T cells, we observed the same sharp decline at day 1 in the percentage and absolute number of human CD3+ and CD8+ T cells in the peripheral blood. There followed an initial increase in the percent of CD3+ cells out of CD45+ cells on day 3 and day 7 in the CD19xCD3-treated group, although this increase was not reflected in the absolute numbers of CD3+ cells per microliter of blood (Figure 4c,d). The percentages of CD8+ cells out of CD3+ cells were also higher in the CD19xCD3-treated animals on days 3, 7, and 14. However, there was not a significant difference in the absolute
Human B cell depletion in vivo by DART proteins

P Tsai et al.

Figure 6  Human CD19+ B-cell depletion by CD19xCD3 DART protein is dependent on the presence of human CD8+ T cells. NSG/BLT mice were administered CD8-depleting antibody (CD8-depleted, n = 8, 3 mg/kg i.v.) or vehicle (CD8-intact, n = 7) 4 days prior to administration of CD19xCD3 DART protein to all mice (1 mg/kg i.v.). Peripheral blood (PB) was collected and analyzed at days 4 and 1 day prior to and at days 3, 7, and 14 after administration of CD19xCD3 DART protein; tissues were harvested and analyzed at day 15. (a) Percent CD19+ cells out of CD45+ cells and (b) number CD19+ cells per microliter detected in PB by flow cytometry (CD8-depleted in orange, CD8-intact in green). (c) Percent CD19+ cells out of CD45+ cells and (d) number CD19+ cells detected in tissues by flow cytometry. (Mean ± SEM plotted. P values were calculated in a and b by repeated-measures two-way analysis of variance with Sidak’s multiple comparisons test, comparing CD8-depleted vs. CD8-intact. P values were calculated in c and d by unpaired t-test, comparing CD8-depleted versus CD8-intact. ns, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.)

numbers of CD8+ cells at day 3 or day 7, and the CD19xCD3-treated animals had lower numbers of CD8+ cells on day 14 (Figure 4e,f). By day 28, there were no significant differences between the groups in the percentages or absolute numbers of peripheral blood human CD45+, CD3+, or CD8+ cells.

At harvest on day 28, there was a small but statistically significant increase in the percentage of CD8+ cells out of CD3+ cells in the bone marrow and spleen of the CD19xCD3-treated animals: 18.2% ± 1.5 (vehicle) versus 28.6% ± 1.8 (CD19xCD3) (P < 0.05) and 14.9% ± 1.3 (vehicle) versus 19.7% ± 0.5 (CD19xCD3) (P < 0.01), respectively (Figure 4g). The percentages of CD8+ cells were not significantly different in the livers or the lungs of these mice. We observed no difference in the total number of CD8+ cells in any of the tissues analyzed (Figure 4h). These results demonstrate that exposure to the CD19xCD3 DART molecule does not have a significant effect on the levels of human CD8+ T cells in peripheral blood or tissues.

Dependence of CD19xCD3 DART protein-mediated depletion on the presence of human CD8+ T cells

To investigate the mechanism of action in vivo of the CD19xCD3 DART molecule, we evaluated the necessity of human CD8+ T cells for target B-cell depletion. One group of BLT mice was administered a CD8-depleting antibody (anti-CD8α antibody MT807R1, kindly provided by Dr Guido Silvestri)39,40 i.v. at 3 mg/kg (CD8-depleted group, n = 8), and one group was administered vehicle (normal saline, CD8-intact group, n = 7). Four days later, both groups were administered CD19xCD3 one time i.v. (1 mg/kg). Peripheral blood was collected and analyzed at 4 days and 1 day prior to and at days 3, 7, and 14 after administration of CD19xCD3 DART protein; tissues were harvested and analyzed at day 15 (Figure 5a).

To confirm depletion of human CD8+ T cells, we measured the levels of CD8+ cells in the peripheral blood and tissues. By 3 days after administration of the CD8-depleting antibody (or 1 day prior to CD19xCD3 administration), the percentage of CD8+ cells out of CD3+ cells decreased to <0.3% ± 0.1, and the number of CD8+ cells decreased to 2 ± 0.7 CD8+ cells per microliter peripheral blood in the CD8-depleted group. The levels of CD8+ cells in the CD8-intact group were 19% CD8+ out of CD3+ and 528 CD8+ cells per microliter at this time point (Figure 5b,c). In the tissues (harvested at day 15 after CD19xCD3 administration), the percentage of CD8+ cells decreased to <1% in the bone marrow and <0.5% in the spleen, liver, and lung of the CD8-depleted mice (Figure 5d); the number of CD8+ cells were reduced 28-fold in the bone marrow, 89-fold in the spleen, 186-fold in the liver, and 110-fold in the lung in the CD8-depleted animals as compared to the CD8-intact group (Figure 5e).

Similar to previous experiments, the human CD19+ B cells were virtually completely depleted in the peripheral blood of the CD8-intact mice (Figure 6a,b). In contrast, in the CD8-depleted mice, we observed only a transient decline in the levels of CD19+ cells at day 7. The differences in the levels of CD19+ cells between the CD8-intact animals and the CD8-depleted animals were statistically significant at days 7 and 14.

Consistent with the depletion of the human CD19+ B cells from the peripheral blood, the levels of CD19+ cells in the tissues were also significantly reduced in the CD8-intact group as compared to the CD8-depleted group (Figure 6c). Even though there was no difference between the groups in number of total bone marrow CD19+ cells, there was at least a 10-fold statistically significant reduction in the total number of CD19+ cells in the spleen, liver, and lung of the CD8-intact versus CD8-depleted animals (Figure 6d). Together, these results...
ery at 24–72 hours. This transient lymphopenia could be explained by redistribution of lymphocytes that are adhering to blood vessels or migrating into tissues. Despite temporary differences, peripheral blood human CD45+, CD3+, and CD8+ cell levels in the CD19xCD3 DART protein-treated animals returned to similar levels as the vehicle group by day 28 after the first injection (Figure 4a,f). Notably, the number of human CD8+ T cells were not significantly different between the vehicle- and CD19xCD3 DART protein-treated animals in the bone marrow, spleen, liver, and lung (Figure 4h).

Finally, we evaluated the dependence of target human CD19+ B-cell depletion by CD19xCD3 DART molecules on the presence of human CD8+ T cells. BLT mice that were CD8-depleted prior to CD19xCD3 administration did not exhibit the reduction of CD19+ cells in the peripheral blood that was observed in CD8-intact animals (Figure 6b,c), and the CD8-depleted group had significantly higher systemic levels of CD19+ cells, except in the bone marrow (Figure 6d,e). These data suggest that human CD8+ T cells are required for depletion of human CD19+ B cells by CD19xCD3 DART molecules.

This study validates the humanized BLT mouse as a preclinical model for the use and evaluation of bispecific reagents, in particular DART molecules. The BLT mouse model provides opportunities to study the in vivo effects of bispecific molecules on human target cells both in the peripheral blood and the tissues. Future directions could include the evaluation of DART molecules directed against other target immune cells or against viral antigens expressed on infected cells. A recent paper from Sung et al.43 showed data on the efficacy ex vivo of a DART molecule directed against HIV envelope protein, thus providing a rationale for further in vivo studies in BLT humanized mice of DART molecules as a targeted cytotoxic therapy against HIV-infected cells, as we have previously demonstrated using an immunotoxin strategy.44

**MATERIALS AND METHODS**

**Ethics statement**

All animal experiments were conducted following NIH guidelines for housing and care of laboratory animals and in accordance with University of North Carolina at Chapel Hill (UNC Chapel Hill) regulations after review and approval by the UNC Chapel Hill Institutional Animal Care and Use Committee (permit number 12–171).

**Generation of BLT humanized mice**

BLT mice were generated as described previously.22 NOD/SCID-γ chain null mice (NSG, Stock #5557, The Jackson Laboratory, Bar Harbor, ME) were sublethally irradiated, implanted with human thymus and liver tissue, and transplanted with autologous human liver CD34+ cells (Advanced Bioscience Resources, Rockville, MD); then they were monitored for human reconstitution in peripheral blood by flow cytometry.23,24,25 All BLT mice (n = 31) used for these experiments contained an average of 63.5% ± 13.6 SD human CD45+ cells in the peripheral blood, of which 39% ± 9.3 SD expressed human CD19, and 53.3% ± 10.7 SD expressed CD3 on their cell surface. 78.3% ± 6.5 SD of human CD3+ cells expressed human CD4.

**DART molecules**

As described by Moore et al.,26 the CD19xCD3 DART molecule, in basic format, was constructed using anti-human CD19 Fv sequences from HD37 (ref. 45) and anti-human CD3 Fv sequences from TR66 (refs. 38,46); and the irrelevant arm of the control DART molecule (4420xCD3) was constructed from anti-fluorescein Fv sequences from 4-4-20 (ref. 47). The binding arms of this CD19xCD3 DART protein do not crossreact with murine antigens. The DART proteins were produced in CHO-S cells and purified as described.20

**Treatment of BLT mice**

BLT mice were injected intravenously with CD19xCD3 DART molecule (MacroGenics, Rockville, MD) at a dose of 1 mg/kg either one time or two times 7 days apart, with 4420xCD3 DART molecule at a dose of 1 mg/kg two times 7 days apart, or with vehicle (normal saline, 0.9% sodium chloride, #0409-4888-10, Hospira, Lake Forest, IL). For CD8+ T-cell depletion, BLT mice were injected i.v. with CD8-depleting antibody (anti-CD8a antibody MT807R1, gift from Dr Guido Silvestri, Atlanta, GA) at a dose of 3 mg/kg or with vehicle (normal saline).
Analysis of BLT mice
Peripheral blood and tissues were collected and cells isolated as previously described for flow cytometric analysis. Antibodies used in these experiments included anti-human CD45 APC (clone HI30, catalog #555485), CD45 FITC (2D1, 347463), CD3 FITC (H3T3a, 555339), CD8 APC-Cy7 (SK1, 557834), CD8 PerCP (SK1, 347314), CD19 PE-Cy7 (SJ25C1, 557835), CD10 APC (HI10a, 340923) (BD Biosciences, San Jose, CA). Flow cytometry data were acquired using a BD FACSCan™ Cytometer and analyzed using BD FACS® Diva software (version 6.1.3) with the following gating strategy: live cells → human CD45+ → human CD19+ (→ human CD10+) or live → human CD45+ → human CD3+ → human CD8+. The numbers of cells per microliter peripheral blood were calculated by dividing the number of positive events acquired by the number of microliters of peripheral blood stained. The numbers of cells per tissue were calculated by multiplying the total number of live cells isolated from the tissue, by the fraction of positive events over live events. Cytokine analysis was performed on plasma samples using a Human Inflammatory Cytokine Kit (551811, BD Biosciences, San Jose, CA); these data were acquired using a BD LSR II Cytometer and analyzed using FCAP Array™ software (Soft Flow, St Louis Park, MN).

Statistical analysis
All statistical tests were performed with an alpha level of 0.05. Repeated-measures two-way analysis of variance with Sidak’s multiple comparisons test was used to generate the P values in Figures 1b—e, 3b, 4a—f, 5b,c, and 6a,b. Unpaired t-test was utilized to generate the P values in Figures 2, 3d,f, 4g,h, 5d,e, and 6c,d. Graphs were generated in Graphpad Prism (version 6).

CONFLICT OF INTEREST
PT, W.O.T., G.S., and J.V.G. have no conflicts of interest to declare. L.L. and J.L.N. are employees of MacroGenics, Inc.

ACKNOWLEDGMENTS
This work was supported in part by grants AI112487-02, AI096113, AI111899, and by Ms. Chichili, GR, Huang, L, Li, H, Tang, Q et al. (2015). A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med 7: 289ra82.

4 Liu, L, Alderson, R, Yang, Y, Li, H, Long, V et al. (2014). MGD011, humanized CD19 x CD3 DART(R) protein with enhanced pharmacokinetic properties, demonstrates potent T-cell mediated activity in preclinical models and durable B-cell depletion in cynomolgous monkeys following once-a-week dosing. Blood 124: 1775.

5 Lan, P, Tomonura, N, Shimizu, A, Wang, S, and Yang, YG (2006). Reconstitution of a mouse-human chimeric monoclonal antibody. J Immunol 177: 4542–4551.

6 Melkus, MW, Estes, JD, Padgett-Thomas, A, Gatlin, J, Denton, PW, Othieno, FA et al. (2006). Humanized mice mount specific adaptive and innate immune responses to EBV and TSS'T-1. Nat Med 12: 1316–1322.

7 Sun, Z, Denton, PW, Estes, JD, Othieno, FA, Wei, BL, Wege, AK et al. (2007). Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204: 705–714.

8 Denton, PW, Estes, JD, Sun, Z, Othieno, FA, Wei, BL, Wege, AK et al. (2008). Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 5: e16.

9 Denton, PW, Skoetz, N, Baur, K, Elter, T, Monsef, I, Roloff, V, Hallek, M et al. (2010). Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 32: 149–165.

10 Castilho, J, Winter, E, and Quesenberry, P (2008). Newer monoclonal antibodies for hematological malignancies. Exp Hematol 36: 755–768.

11 Saret, CJ, Winn, AN, Shah, G, Parsons, SK, Lin, PJ, Cohen, JT et al. (2015). Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood 125: 1866–1869.

12 Cheson, BD and Leonard, JP (2008). Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 359: 613–626.

13 Cheson, BD (2010). Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28: 3525–3530.

14 Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850–854.

15 Kochenderfer, JN, Xu, Z, Frascheri, D, Restifo, NP and Rosenberg, SA (2010). Adoptive transfer of engineered T cells using a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116: 3875–3886.

16 Maus, MV, Grupp, SA, Porter, DL and June, CH (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123: 2625–2635.

17 Topp, MS, Gökbüget, N, Zugmaier, G, Degenhardt, E, Goebeler, ME, Klinger, M et al. (2012). Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120: 5158–5167.

18 Johnson, S, Burke, S, Huang, L, Gorlatov, S, Li, H, Wang, W et al. (2010). Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolyis and in vivo B-cell depletion. Mol Biol Cell 39: 436–449.

19 Moore, PA, Zhang, W, Rainey, GJ, Burke, S, Li, H, Huang, L et al. (2011). Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 117: 4542–4551.

20 Chichili, GR, Huang, L, Li, H, Tang, Q et al. (2015). A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med 7: 289ra82.

21 Liu, L, Alderson, R, Yang, Y, Li, H, Long, V et al. (2014). MGD011, humanized CD19 x CD3 DART(R) protein with enhanced pharmacokinetic properties, demonstrates potent T-cell mediated activity in preclinical models and durable B-cell depletion in cynomolgous monkeys following once-a-week dosing. Blood 124: 1775.

22 Lan, P, Tomonura, N, Shimizu, A, Wang, S, and Yang, YG (2006). Reconstitution of a mouse-human chimeric monoclonal antibody. J Immunol 177: 4542–4551.

23 Skoetz, N, Baur, K, Elter, T, Monsef, I, Roloff, V, Hallek, M et al. (2010). Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 32: 96–104.

24 Cheson, BD, and Leonard, JP (2008). Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 359: 613–626.

25 Castilho, J, Winter, E, and Quesenberry, P (2008). Newer monoclonal antibodies for hematological malignancies. Exp Hematol 36: 755–768.

26 Saret, CJ, Winn, AN, Shah, G, Parsons, SK, Lin, PJ, Cohen, JT et al. (2015). Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood 125: 1866–1869.
Human B cell depletion *in vivo* by DART proteins
P Tsai et al.

40 Chowdhury, A, Hayes, TL, Bosinger, SE, Lawson, BO, Vanderford, T, Schmitz, JE et al. (2015). Differential impact of *in vivo* CD8+ T lymphocyte depletion in controller versus progressor simian immunodeficiency virus-infected macaques. *J Virol* **89**: 8677–8686.

41 Sun, LL, Ellerman, D, Mathieu, M, Hristopoulos, M, Chen, X, Li, Y et al. (2015). Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. *Sci Transl Med* **7**: 287ra70.

42 Schliereth, B, Quadt, C, Dreier, T, Kufer, P, Lorenzewscki, G, Prang, N et al. (2006). T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. *Cancer Immunol Immunother* **55**: 503–514.

43 Sung, JA, Pickeral, J, Liu, L, Stanfield-Oakley, SA, Lam, CY, Garrido, C et al. (2015). Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. *J Clin Invest* **125**: 4077–4090.

44 Denton, PW, Long, JM, Wietgrefe, SW, Sykes, C, Spagnuolo, RA, Snyder, OD et al. (2014). Targeted cytotoxic therapy kills persisting HIV infected cells during ART. *PLoS Pathog* **10**: e1003872.

45 Kipriyanov, SM, Kupriyanova, OA, Little, M and Moldenhauer, G (1996). Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry. *J Immunol Methods* **196**: 51–62.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

Supplementary Information accompanies this paper on the *Molecular Therapy—Oncolytics* website (http://www.nature.com/mto)